Gliadin activates arginase pathway in RAW264.7 cells and in human monocytes  by Barilli, Amelia et al.
Biochimica et Biophysica Acta 1842 (2014) 1364–1371
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isGliadin activates arginase pathway in RAW264.7 cells and in
human monocytesAmelia Barilli, Bianca Maria Rotoli, Rossana Visigalli, Valeria Dall'Asta ⁎
Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali (SBiBiT), Università degli Studi di Parma, Via Volturno 39, 43125 Parma, Italy⁎ Corresponding author. Tel.: +39 0521 033787; fax: +
E-mail address: valeria.dallasta@unipr.it (V. Dall'Asta)
http://dx.doi.org/10.1016/j.bbadis.2014.04.021
0925-4439/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 3 February 2014
Received in revised form 10 April 2014
Accepted 25 April 2014
Available online 2 May 2014
Keywords:
Celiac disease
Gliadin
Arginine
Arginase
Interferon-γ
Nitric oxideCeliac disease (CD) is an autoimmune enteropathy triggered in susceptible individuals by the ingestion of gliadin-
containing grains. Recent studies have demonstrated that macrophages play a key role in the pathogenesis of CD
through the release of inﬂammatory mediators such as cytokines and nitric oxide (NO). Since arginine is the
obliged substrate of iNOS (inducible nitric oxide synthase), the enzyme that produces large amount of NO, the
aimof thiswork is to investigate argininemetabolic pathways inRAW264.7murinemacrophages after treatment
with PT-gliadin (PTG) in the absence and in the presence of IFNγ. Our results demonstrate that, besides strength-
ening the IFNγ-dependent activation of iNOS, gliadin is also an inducer of arginase, the enzyme that transforms
arginine into ornithine and urea. Gliadin treatment increases, indeed, the expression and the activity of arginase,
leading to the production of polyamines through the subsequent induction of ornithine decarboxylase. This effect
is strengthened by IFNγ. The activation of these pathways takes advantage of the increased availability of arginine
due to a decreased system y+L-mediated efﬂux, likely ascribable to a reduced expression of Slc7a6 transporter. A
signiﬁcant induction of arginase expression is also observed in human monocytes from healthy subject upon
treatment with gliadin, thus demonstrating that gluten components trigger changes in arginine metabolism in
monocyte/macrophage cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Celiac disease (CD, MIM: 212750) is a chronic, immune-mediated
disorder caused by a permanent intolerance in genetically susceptible
individuals to ingested gluten/gliadin, a protein ofwheat and related ce-
reals [1]. The disease ranges from asymptomatic to severely symptom-
atic, with clinical manifestations including typical gastrointestinal
symptoms, such as diarrhea and abdominal pain or discomfort, but
also extraintestinal manifestations, such as short stature, neurologic
symptoms, or anemia [2]. The clinical heterogeneity of CD develops in
the context of a sustained chronic inﬂammation of the small intestinal
mucosa which is histologically characterized by villous atrophy, crypt
hyperplasia, hypercellularity of the lamina propria and increased
number of intraepithelial lymphocytes (IELs) [3,4]. All morphological
changes are generally reversible during a gluten-free diet.
CD has been strongly associated with HLA-DQ2 or HLA-DQ8
isotypes, responsible of the inappropriate T cell-mediated immune re-
sponse [5–7]. However, studies addressing the onset of CD in identical
twins, as well as the fact that only 2–5% of individual expressing these
HLAs develops the disease, clearly indicate that the expression of HLA-
DQ2/8 is necessary but not sufﬁcient to cause CD, while additional39 0521 033742.
.genetic or environmental factors may have a role in the pathogenesis
of this autoimmune disease [8].
Clinical and experimental ﬁndings ascribe a primary role to the in-
nate immune system in the activation of an early response against
ingested gluten in CD, providing evidences that these events are critical
for the priming of the subsequent adaptive immune responses [9]. In-
nate immune cells, mainly monocytes/macrophages and dendritic
cells (DCs), are, indeed, supposed to interact with gliadin into the intes-
tinal submucosa, leading to the activation of the Ag-speciﬁc adaptive
immune response. Consistently, in vitro studies with intestinal organ
cultures, primary APCs and epithelial and monocytic cell lines, support
the notion that gluten affects the innate immune system to the same ex-
tent as T cells [7]. In particular, gliadin and its peptic fragments are re-
ported to induce the expression of proinﬂammatory genes, cytokines
secretion (TNFα, IL-12, IL-15), and zonulin release in murine macro-
phages [10] and to activate blood monocytes from patients with CD, in
terms of TNF-α and IL-8 production [11].
Among the repertoire of inﬂammatory genes up-regulated by glia-
din peptides, a signiﬁcant up-regulation of inducible nitric oxide
synthase (iNOS) has been described in the small intestinal mucosa
of CD patients [12,13]. Consistently, increased levels of nitric oxide
(NO) metabolites (nitrites and nitrates) are detected in serum and
urine of children with both symptomatic CD or screening-detected,
nonsymptomatic, “silent” CD, pointing to NO metabolites as a pathoge-
netic feature of CD [14–16].
1365A. Barilli et al. / Biochimica et Biophysica Acta 1842 (2014) 1364–1371Nitric oxide is known to exert antibacterial and cytostatic effects;
however, when produced in excessive amounts, it also acts as a free
radical that can cause tissue damage, impairing the function and integ-
rity of the gut barrier and, hence, increasing mucosal permeability [17].
Since the amino acid arginine is the obliged substrate for iNOS, both
its intracellular availability andmetabolismappear of peculiar relevance
for the study of CD pathogenesis. Besides iNOS, that converts arginine to
nitric oxide and citrulline, also arginase is involved in the catabolism of
the amino acid converting it to urea and ornithine. The two enzymes are
speciﬁcally induced during classical (type I orM1) or alternative (type II
or M2) macrophage activation, respectively. In particular, classically
activated macrophages produce copious amounts of nitric oxide, as
well as of pro-inﬂammatory cytokines, as a defense against intracellular
pathogens. In contrast, alternatively activated macrophages exert anti-
inﬂammatory properties and mediate tissue homeostasis and repair
through the arginase dependent production of polyamines and proline,
which are involved in cell proliferation and collagen production,
respectively.
Intracellular arginine levels are regulated by the uptake of the extra-
cellular amino acid via speciﬁc transporters [18]. In particular, arginine
transport in non-epithelial models is mediated by system y+ and
system y+L. System y+ activity, referable to the CAT family of
monomeric transporters, mediates a sodium-independent, membrane
potential-sensitive arginine transport. Conversely, system y+L consists
of a group of heterodimeric amino acid transporters formed by a
heavy subunit (4F2hc/CD98, the product of SLC3A2 gene) and one of
two alternative light chains, y+LAT1 (encoded by SLC7A7) or y+LAT2
(encoded by SLC7A6), and operates as an antiport that couples the
ﬂux of arginine with that of neutral amino acids and sodium [18].
While the activity of system y+ is mainly responsible for the intracellu-
lar accumulation of arginine, system y+L likely acts as an efﬂux route for
the amino acid [19–21].
In the present paper we investigate the effects of the treatmentwith
gliadin on arginine metabolism in RAW264.7 murine macrophages and
in human monocytes.2. Materials and methods
2.1. Cell culture and experimental treatments
RAW264.7 murine macrophages were obtained from the Istituto
Zooproﬁlattico Sperimentale della Lombardia ed Emilia-Romagna.
Cells were routinely cultured in RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, and
kept at 37 °C, pH 7.4, in an atmosphere of 5% CO2.
For the experiments, RAW264.7 cells were seeded in multi-well
Falcon dishes at the density of 100,000/ml and incubated the day after
in the presence of 10 ng/ml IFNγ, 1 mg/ml gliadin peptic–tryptic pep-
tides (PTG) or both, as indicated.
Human peripheral bloodmononuclear cells (PBMC)were isolated by
Lympholite® (EuroClone, Milano, Italy) gradient separation of blood
samples obtained from healthy donors (approved by Local Ethics Com-
mittee N° 37863 del 14/11/2013). Monocytes were puriﬁed from PBMC
by positive selection using magnetic cell separation columns and CD14
MicroBeads (Miltenyi Biotec, Bologna, Italy). Highly enrichedmonocytes
(10^6 cells/ml) were incubated in RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at
37 °C, pH 7.4, in an atmosphere of 5% CO2 in the absence or in the
presence of PTG.
PTG was obtained through enzymatic digestion of 50 g of gliadin
(Sigma-Aldrich, Milano, Italy) by incubation for 2 h at 37 °C in the pres-
ence of 1 g pepsin (Sigma-Aldrich) in 500 ml HCl 0.2 N. The resulting
product was further digested by addition of 1 g trypsin (Sigma-Aldrich)
and the pH adjusted to 7.4with NaOH 2M. The solutionwas stirred vig-
orously at 37 °C for 4 h, boiled (100 °C) for 30min, cooled off, stocked inaliquots and conserved at−20 °C. Endotoxin contamination, assessed
with an E-TOXATE kit (Sigma-Aldrich), was below 4.8 EU/ml.
2.2. Intracellular arginine content and metabolism
The study of arginine conversion into its metabolites has been per-
formed employing an original technique developed in our lab [22].
Cells were treated as required by the experimental plan in complete
growth medium containing L-[14C(U)]arginine (5 μCi/ml). At the end
of the treatment, the intracellular amino acid pool was extracted in a
5% solution of acetic acid in ethanol, lyophilized, and re-suspended in
150 μl of Lithium Loading Buffer pH 2.2 (Biochrom, Cambridge, UK).
50 μl were employed immediately for measuring whole radioactivity
with a Wallac MicroBeta TriLux2 liquid scintillation spectrometer
(PerkinElmer, Monza, Italy), while the remaining 100 μl were injected
on Biochrom 20 Amino Acid Analyzer and separated by employing a
High Resolution Column Bio 20 Peek Lithium and the Physiological
Fluid Chemical Kit (Biochrom). The resulting eluting fractions were col-
lected into 96-well trays (192 samples; 40 s/fraction), dried by heating
at 45–50 °C and resuspended in 50 μl of ethanol. Radioactivity in each
well was determined and CPM in each fraction were plotted as a func-
tion of their Retention Time (Tr). Standard samples containing known
radiolabeled amino acids were run in parallel and employed to identify
the metabolite in each fraction. Finally, extracted cells were dissolved
with 0.5% sodium deoxycholate in 1 M NaOH and protein content was
determined directly in the well using a modiﬁed Lowry procedure [23].
2.3. NO production
The production of NO was assessed through the quantiﬁcation of
nitrites, stable derivatives of NO, in the culture media, as already
described [24]. A ﬂuorimetric approach was employed, based on the
production of the ﬂuorescent molecule 1-(H)-naphthotriazole from
DAN in the presence of nitrite in an acid environment. Fluorescence
was determinedwith EnSpire®Multimode Plate Reader (PerkinElmer).
Nitrite production was expressed in nmoles per ml of extracellular
medium (μM).
2.4. Arginase activity
Arginase activity was determined with QuantiChrom™ Arginase
Assay Kit by BioAssay Systems (Valter Occhiena, Torino, Italy). Lysates
obtained from 106 cells were incubated for 2 h at 37 °C in the presence
of 5× Substrate Buffer. The reactionwas then stopped by the addition of
Urea Reagent and, after 1 h, optical absorbance at 430 nmwas readwith
EnSpire® Multimode Plate Reader (PerkinElmer). Protein content was
determined for each sample using a modiﬁed Lowry procedure [23]
and arginase activity was expressed as U/L/μg of protein.
2.5. qRT-polymerase chain reaction
1 μg of total RNA, extracted with GenElute™Mammalian Total RNA
Miniprep Kit (Sigma-Aldrich) was reverse transcribed and 40 ng of
cDNA were ampliﬁed as described previously [25]. The sequence of
the forward and reverse primers employed is listed in Table 1. The
expression of the gene of interest under each experimental condition
was normalized to that of the housekeeping gene Gapdh (for RAW264.7
cells) or RPL-15 (for human monocytes) and shown relatively to its
expression level in control, untreated cells (=1).
2.6. Western Blot analysis
Cells were washed with ice-cold PBS and suspended in Laemmli
buffer (62.5 M Tris–HCl, pH 6.8, 2% SDS, 20% glycerol, 0.2 M DTT).
Western Blot analysis was performed as previously described [26],
using anti-iNOS (1:1000) and anti-Arginase II (1:500) puriﬁed rabbit
Table 1
Primers employed for qRT-PCR analysis.
Forward primer Reverse primer
ArgII CTGGCTGAAGTGGTTAGTAGA GGGCGTGACCGATAAT
Nos2 GTTCTCAGCCCAACAATACAAGA GTGGACGGGTCGATGTCAC
Oat GGAGTCCACACCTCAGTCG CCACATCCCACATATAAATGCCT
Odc GACGAGTTTGACTGCCACATC CGCAACATAGAACGCATCCTT
Slc7a1 GGAGTGCGACTTTTGACGAG ACCAGGACATTGATACAGGTGA
Slc7a2 TCCCAATGCCTCGTGTAA CCCGACGACAAAGTAGCA
Slc7a6 CCTACTCGGGCTGGGACAC AGGTAGATGATGGTGACGATTGGC
Slc7a7 TTATTAGGAATGTGCTGGCTACTG GGTTTAGGGAACTGGTCTTTG
Gapdh TGTTCCTACCCCCAATGTGT GGTCCTCAGTGTAGCCCAAG
ARGII AAGCTGGCTTGATGAAAAGGC GCGTGGATTCACTATCAGGTTGT
RPL-15 GCAGCCATCAGGTAAGCCAAG AGCGGACCCTCAGAAGAAAGC
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Italy) in blocking solution. GAPDH or actin, detected with a polyclonal
antibody (1:1000, Sigma-Aldrich), were employed as internal standard.
Immunoreactivity was visualized with enhanced chemiluminescence
(Millipore, Milano, Italy).2.7. Arginine inﬂux
For transport studies, experiments were carried out on cell cultures
resulting from 3 × 104 cells seeded into 96-well trays. Cells, washed
once with a modiﬁed bicarbonate-free Earle's Balanced Salt Solution
(EBSS) buffered at pH 7.4 with 20 mM Tris/HCl, were incubated for
1 min in the same solution containing L-[3H]arginine (5 μCi/ml,
100 μM) in the absence or in the presence of 2 mM leucine or 2 mM
leucine + 2 mM lysine. The experiment was terminated by two rapid
washes (b10 s) in ice-cold urea and cell monolayers were extracted in
ethanol. The radioactivity in cell extracts was determined with Wallac
Microbeta Trilux2 liquid scintillation spectrometer (PerkinElmer). Pro-
tein content was determined directly in the well using a modiﬁed
Lowry procedure [23]. Arginine inﬂux is expressed as nmol/mg of pro-
tein/min. The contribution of system y+L, the leucine-inhibitable com-
ponent, was calculated from the difference between total inﬂux and
the inﬂuxmeasured in the presence of leucine, while the activity of sys-
tem y+ corresponds to the difference between the inﬂux measured in
the presence of leucine and the inﬂux measured in the presence of
leucine + lysine (see [27] for details).2.8. L-arginine efﬂux
Cells, loaded with [3H]-arginine (50 μM, 10 μCi/ml) in EBSS for 10
min, were washed twice with arginine-free EBSS (efﬂux medium)
and incubated in 0.15 ml of the same solution in the absence or in the
presence of 1 mM leucine [28]. At the indicated times efﬂux medium
was removed, replacedwith freshmediumand counted for radioactivity.
Cell monolayers were extracted in 50 μl of ethanol and radioactivity in
the extracts was counted so as to measure arginine remained within
the cells. The percent of arginine efﬂux at each time was calculated
with the formula: [efﬂux medium counts/(intracellular counts + total
efﬂux media counts)], %. System y+L-mediated efﬂux was calculated as
the difference between efﬂux measured in the presence and in the ab-
sence of leucine at any time.2.9. Statistical analysis
Student t test for unpaired data was used for statistical analysis of
differences between control and each single treatment. Differences
were considered signiﬁcant when the associated probability value (p)
was b0.05.2.10. Materials
RPMI-1640 and endotoxin-free FBS were purchased from EuroClone
(Milano, Italy). [L-2,3,4-3H]arginine (45–70 Ci/mmol) and L-[14C(U)]argi-
nine (274 mCi/mmol) was obtained from PerkinElmer (Monza, Italy).
IFNγ was purchased from VWR International PBI s.r.l. (Milano, Italy).
Microtech s.r.l. (Napoli, Italy) provided Falcon plastic disposable. Sigma-
Aldrich (Milano, Italy) was the source of gliadin, and, unless otherwise
speciﬁed, of all the other chemicals.
3. Results
3.1. Effects of PTG and IFNγ on intracellular arginine accumulation and
metabolism in RAW264.7 cells
Since arginine is the obliged substrate for the synthesis of nitric
oxide (NO), we have ﬁrst evaluated whether the treatment of murine
macrophages with gliadin peptic–tryptic peptides (PTG) modiﬁes the
intracellular bioavailability of the amino acid. To this aim RAW264.7
cells were incubated in medium containing radiolabeled [14C]arginine
and treated for 24 h with PTG, in the absence and in the presence of
IFNγ, the cytokine secreted by activated CD4+ T-cells. At the end of
the treatment intracellular radioactivity wasmeasured under all exper-
imental conditions. Results, shown in Fig. 1A, clearly indicate that the in-
cubation with IFNγ, but not PTG, causes a signiﬁcant accumulation of
radiolabeled [14C]arginine within the cells. The simultaneous addition
of the two compounds further enhances the amount of intracellular ra-
dioactivity, which is doubled with respect to control, untreated cells,
and signiﬁcantly higher than in IFNγ-treated cells.
To evaluate which amount of the radioactivity measured within the
cells is actually arginine or is rather due to a transformation of the amino
acid into itsmetabolites, we have performed a chromatographic separa-
tion of the extracted pool andmeasured radioactivity in all elution frac-
tions. The resulting plot (Fig. 1B) indicates that, beside the peak of
arginine (Tr = 115 min), only another one, corresponding to poly-
amines (Tr = 130–140 min), is readily distinguishable in untreated,
control cells. This result points to a basal activity of arginase in this cell
model. As expected, the addition of IFNγ causes the appearance of the
peak of citrulline (Tr = 47 min) that demonstrates the activation of
NO pathway. No signiﬁcant change of polyamines production is detect-
able under this condition. On the contrary, the treatment with PTG
causes an increase of polyamines fractions that suggests the stimulation
of arginase activity, and no change of citrulline peak. When IFNγ and
PTG are simultaneously present, the effects of the two compounds ap-
pear reciprocally strengthened: peaks corresponding to citrulline and
polyamines are, indeed, higher than those observed upon incubation
with either compounds alone.
3.2. Effects of PTG and IFNγ on iNOS and arginase expression and activity in
RAW264.7 cells
The metabolic proﬁles obtained for arginine under the different ex-
perimental conditions have been, then, validated at functional level.
Consistently with previously reported studies performed in mouse
peritoneal macrophages and in RAW264.7 cells [29–32], the treatment
of the cells with PTG, which causes per se an only modest increase of
nitric oxide (NO) production, signiﬁcantly strengthens the stimulatory
effect of IFNγ (Fig. 2A), through the induction of iNOS enzyme at both
gene and protein levels (Fig. 2B–C). As revealed by the time course
analysis of Nos2mRNA, the synergic effect of PTG on IFNγ-dependent
stimulation of gene expression is particularly evident for short term
treatments (4 and 8 h), while lowering at 24 h.
The increased production of polyamines observed upon incubation
with PTG prompt us to explore also the pathway of arginase (ARG). As
shown in Fig. 3A, a signiﬁcant stimulation of the enzymatic activity
occurs upon treatment with PTG alone, but not with IFNγ. When the
Fig. 1. Effects of IFNγ and PTG on arginine accumulation and metabolism. RAW264.7 cells were either untreated (control) or treated with 10 ng/ml IFNγ, 1 mg/ml PTG or both in complete
growthmedium addedwith L-[14C(U)]arginine (5 μCi/ml). After 24 h, the intracellular amino acid poolwas extracted. Radioactivity under each conditionwas counted directly (Panel A) or
separated in 192 fractions throughHPLC,measured in each fraction and plotted as function of retention time (Tr), as described inMethods (Panel B). Amagniﬁcation of peaks correspond-
ing to arginine (Arg) and polyamines is given in the Insert. Data of Panel A aremeans± SEM of 4 experiments, one ofwhich is shown in Panel B. *p b 0.05, **p b 0.01 vs. control, untreated
cells; $p b 0.05 vs. IFNγ-treated cells.
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activity can be observed. The activation of arginase is associated to
an increased expression of the enzyme at both mRNA and protein
level (Fig. 3B–C). In particular, a signiﬁcant increase of arginase
transcript is appreciable starting from 8 h of treatment with PTG.
The simultaneous presence of IFNγ and PTG causes a late hyper-
expression of the mRNA whose levels, after 24 h, becomes at least ﬁve
folds higher than in PTG-treated cells (Fig. 3B). TheWestern Blot analy-
sis of the protein conﬁrms these results: poorly detectable in control
and in IFNγ-treated cells, ARG expression becomes evident upon treat-
ment with PTG and, even more, in the simultaneous presence of IFNγ
(Fig. 3C).
In order to pursue the metabolic pathway of arginase products, we
investigated the expression of ornithine decarboxylase (Odc), the en-
zyme that converts ornithine to polyamines (putrescine, spermine and
spermidine) andornithine aminotransferase (Oat) that transforms orni-
thine to glutamate and proline. Results, presented in Fig. 4, show that
Odc expression is signiﬁcantly stimulated by PTG, conﬁrming the activa-
tion of the pathway leading to polyamines production; IFNγ does not
modify PTG effect. On the contrary, the expression of Oat is slightly de-
creased by IFNγ, both in the absence and in presence of PTG.3.3. Effects of IFNγ and PTG on arginine transport activity in RAW264.7 cells
A preliminary characterization of arginine transport in RAW264.7
has been performed, according to the strategy already used in other
cell models [24,25,27]. As shown in Fig. 5A, the addition of leucine, a
substrate of system y+L in the presence of Na+, inhibits arginine inﬂux
by more than 70% indicating that most of arginine uptake occurs
through this route. The further addition of lysine produces a modest
further decrease of arginine transport, thus indicating amarginal contri-
bution of system y+ in these cells.
The effects of PTG and IFNγ on the discriminated arginine transport
has been then evaluated. As shown in Fig. 5B, the activity of system y+ is
not modiﬁed by any of the experimental treatments, whereas the activ-
ity of system y+L decreases upon incubation with IFNγ, both in the
absence or in presence of PTG.Under the same experimental conditions, the efﬂux of arginine
through system y+L has also been evaluated.While control cells exhibit
amarked systemy+L-mediated arginine efﬂux, in IFNγ–treated cells the
efﬂux of the amino acid appears signiﬁcantly reduced. After 1 min, in-
deed, control cultures release about 60% of pre-accumulated arginine,
while IFNγ–treated cells only 20%. The simultaneous addition of PTG,
that per se only slightly reduces arginine efﬂux, further strengthens
the effect of IFNγ (Fig. 6).
The effects of the compounds have been assessed also on the expres-
sion of genes coding for arginine transporters. As shown in Fig. 7,
the treatment with PTG does not change the expression of any of the
arginine carriers, while IFNγ modiﬁes both system y+- and system
y+L-related transporters. In particular, the expression of Slc7a2 and
Slc7a7 are signiﬁcantly induced by the cytokine, while Slc7a1 and
Slc7a6 appear clearly decreased.
3.4. Effects of PTG on arginase expression in human monocytes
In additional experiments, the effect of PTG has been preliminary
investigated on healthy human monocytes. As shown in Fig. 8A,
the treatment with PTG causes the induction of arginase mRNA in
monocytes isolated from six different donors, with expression levels 2
to 12 fold higher than in control, untreated cells. Consistently, an
increased expression of the enzyme at protein level can be observed
in PTG-treated monocytes, as conﬁrmed by Western Blot analysis
(Fig. 8B). Comparable results have been obtained employing a synthetic
peptide whose sequence corresponds to a part of the 33-mer gliadin
peptide known to be immunogenic for humans [33] (data not shown).
4. Discussion
In the present study we provide evidence, for the ﬁrst time, about
the ability of gliadin to stimulate argininemetabolism through the acti-
vation of arginase pathway in RAW264.7 mouse macrophages and in
human monocytes.
Previous studies have demonstrated that gluten/gliadin and their
proteolitic fragments strengthens the stimulatory effect of IFNγ on
Fig. 2. Effects of IFNγ and PTG on nitric oxide production and iNOS expression. Cells were
either untreated (control) or treated with 10 ng/ml IFNγ, 1 mg/ml PTG or both in com-
plete growthmedium. After 24 h theproduction of nitric oxide (NO)was assessed through
the quantization of nitrites in the incubationmedium (Panel A). At the times indicated, the
expression of Nos2was determined through qRT-PCR analysis and shown, after normali-
zation to Gapdh, as fold induction relatively to control, untreated cells (=1) (Panel B).
Data aremeans±SEMof 3 experiments, each performed in triplicate. After 24 h-treatment,
Western Blot analysis was performed using anti-iNOS and anti-actin antibodies (see
Methods). A representative Western Blot is shown (Panel C). The experiment was
repeated three times with comparable results. ***p b 0.001 vs. control, untreated cells;
$p b 0.05, $$$p b 0.001 vs. IFNγ-treated cells at the corresponding time-point.
Fig. 3. Effects of IFNγ and PTG on arginase pathway. RAW264.7were left untreated (control)
or incubated in the presence of 10 ng/ml IFNγ, 1 mg/ml PTG or both in complete growth
medium. After 24 h arginase activity was measured as described in Methods (Panel A).
Data are means ± SEM of 3 experiments, each performed in triplicate. The expression of
Arg was determined through RT-qPCR at the times indicated (Panel B). Data, shown
after normalization to Gapdh as fold induction relatively to control, untreated cells (=1),
are means ± SEM of 3 experiments, each performed in triplicate. After 24 h-treatment,
Western Blot analysis was performed using anti-ARG and anti-GAPDH antibodies (see
Methods). A representative Western Blot is shown (Panel C). The experiment was
repeated three times with comparable results. *p b 0.05; **p b 0.01, ***p b 0.001 vs. con-
trol, untreated cells; &&p b 0.01, &&&p b 0.001 vs. PTG-treated cells at the corresponding
time-point.
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in mouse peritoneal macrophages [29,31]. Accordingly, high levels of
NO derivatives are detectable in vivo, in the serum and urine of children
with celiac disease, and correlate with an increased expression of iNOS
in the small intestine [15,16,34,35]. Although the precise mechanisms
through which NO may directly or indirectly induce tissue damage in
CD are not completely understood [14], those ﬁndings point to a patho-
genetic role of NO in the onset of celiac disease.
By addressing the whole metabolic proﬁle of arginine in RAW264.7
cells, we show here that, besides the expected conversion of the
amino acid to citrulline and NO upon incubation with IFNγ, another
metabolic pathway is activated in the presence of PTG that leads to an
increased production of polyamines (see Fig. 1). As demonstrated atbothmolecular and functional levels, this effect is attributable to the ac-
tivation of arginase, the enzyme that converts arginine to ornithine and
urea, and to the subsequent induction of Odc, which synthesizes poly-
amines from ornithine (see Figs. 3 and 4).
Interestingly, the effects of IFNγ and PTG on arginine metabolism,
which diverge when the two compounds are employed alone, appear
mutually strengthened during a combined treatment (see Figs. 2–4).
Thus, when RAW264.7 cells are exposed to PTG and IFNγ, they present
features of both classically M1 and alternatively M2 activated macro-
phages. The pro-inﬂammatory (M1) phenotype, likely responsible
for tissue damage, is mainly ascribable to IFNγ, while the anti-
inﬂammatory (M2) phenotype is induced by PTG and leads to the syn-
thesis of polyamines, well known modulators of cell proliferation and
differentiation.
Fig. 4. Effects of IFNγ and PTG on Odc and Oat expression. RAW264.7 were left untreated
(control) or incubated in the presence of 10 ng/ml IFNγ, 1 mg/ml PTG or both in complete
growthmedium. At the indicated times, the expression of Odc (Panel A) andOat (Panel B)
were determined through RT-qPCR as described inMethods. Data, shown after normaliza-
tion to Gapdh as fold induction relatively to control, untreated cells (=1), are means ±
SEM of 3 experiments, each performed in triplicate. **p b 0.01, ***p b 0.001 vs. control,
untreated cells at the corresponding time-point.
Fig. 6. Effects of IFNγ and PTG on arginine efﬂux through systemy+L.RAW264.7were left un-
treated (control) or treatedwith 10 ng/ml IFNγ, 1 mg/ml PTG or both in complete growth
medium. After 24 h cells were loaded with L-[3H]arginine (50 μM; 10 μCi/ml) for 10 min.
After washing, cells were incubated in 100 μl EBSS in the absence or in the presence of 1
mM leucine and radioactivity in the efﬂux medium was measured at the indicated
times. At each time, arginine efﬂux corresponds to the fraction in % of the pre-
accumulated [3H]arginine escaped from the cells. System y+L-mediated arginine efﬂux is
calculated as described inMethods. Data aremeans±SEMof 3 independent experiments,
each performed in triplicate.
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mon in macrophages, as the induction of one enzyme usually leads to
the inhibition of the other due to the competition for the commonFig. 5.Arginine transport in RAW264.7: effects of IFNγ and PTG. In Panel A a preliminary characteri
assayed in untreated RAW264.7 with 1-min incubations in EBSS supplemented with L-[3H]argi
leucine + 2 mM lysine, as indicated. Data are means ± SEM of 3 experiments, each performed
presence of 10 ng/ml IFNγ, 1 mg/ml PTG or both for 24 h in complete growth medium. At th
y+ and y+L was calculated as described in Methods. Data are means ± SEM of 3 experiments,substrate arginine. However, it is also known that the upregulation of
arginase expression in macrophages is employed by several pathogens
as a strategy to limit iNOS-dependent host defense [36]. For example,
studies concerning gastritis induced by Helicobacter pylori have shown
that the bacterial infection induces the expression of both arginase II
(Arg2) and Odc in macrophages in vitro and in vivo, and causes an in-
crease in polyamine levels [37]. The same study also demonstrated
that the production of NO derived from iNOS in RAW 264.7 cells stimu-
lated by H. pylori depends on the arginine concentration in the culture
medium. Under our experimental conditions, i.e. in the presence of
non-limiting concentrations of arginine, the activation of the twometa-
bolic pathways takes advantage from the increased availability of the
amino acid inside the cells (see Fig. 1). This condition can be achieved
through either an increased inﬂux or a decreased efﬂux through the
plasma membrane. Previous studies attributed a central role to system
y+ and, speciﬁcally, to Slc7a2/CAT2 in providing arginine for the synthe-
sis of NO in activated macrophages [37,38]. Accordingly, our results in-
dicate that the incubation with IFNγ produces a signiﬁcant induction ofzation of arginine inﬂux has been performed as described inMethods. Arginine uptakewas
nine (50 μM; 5 μCi/ml) in the absence (total) or in the presence of 2 mM leucine or 2 mM
in quadruplicate. In Panel B RAW264.7 were left untreated (control) or incubated in the
is time arginine uptake was measured as described in Panel A and the activity of system
each performed in quadruplicate *p b 0.05 vs. control, untreated cells.
Fig. 7. Effects of IFNγ and PTG on arginine transporters. Cells were left untreated (control) or treated with 10 ng/ml IFNγ, 1 mg/ml PTG or both in complete growth medium. After 24 h the
expression of the indicated genes was evaluated with qRT-PCR and shown, after normalization to Gapdh, as fold induction relatively to control, untreated cells (=1). Data are means ±
SEM of 3 experiments, each performed in triplicate. *p b 0.05; **p b 0.01; ***p b 0.001 vs. control, untreated cells; $p b 0.05 vs. IFNγ-treated cells.
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lation results ineffective at functional level, given that the low basal
activity of system y+ is not modiﬁed by the addition of the cytokine,
both in the absence and in the presence of gliadin (see Fig. 5). Since
a concomitant decrease of Slc7a1/CAT1 expression is detectable in
IFNγ-treated cells (see Fig. 7), we can speculate that the opposite effects
of the cytokine on the expression of the two genes cancel each other,
leaving the activity of system y+ unaltered under any experimental
condition.
Conversely, our ﬁndings clearly indicate that the treatmentwith PTG
and IFNγ markedly affects arginine transport through system y+L
(see Figs. 5 and 6). Since system y+L is known to physiologically medi-
ate arginine efﬂux, rather than inﬂux, exchanging intracellular arginine
with extracellular neutral amino acid plus sodium [19–21], the decrease
of its activity upon incubation with IFNγ and, even more, with IFNγ+
PTG, justiﬁes the increased amount of intracellular arginine observed.
At molecular level, this effect is paralleled by an impressive decrease
of Slc7a6/y+LAT2 and a concomitant induction of Slc7a7/y+LAT1 by
IFNγ (see Fig. 7). A comparable stimulation of Slc7a7/y+LAT1 has
been previously reported by our group in freshly isolated humanmono-
cytes [39] in which, however, a parallel increase of system y+L activity
was observed. In the present study, IFNγ and even more IFNγ+ PTG,
causing a marked decrease of Slc7a6 expression, determines a decrease
in system y+L-mediated arginine transport, demonstrating that, unlike
human monocytes, in mouse macrophages the activity of system y+LFig. 8. Effects of PTG on arginase expression in humanmonocytes. Freshly isolated humanmonocy
ml PTG (Panel A, n = 6 healthy subjects). After 24 h, arginase (ARG) expression was determin
tively to control, untreated cells (=1). A representative Western Blot analysis, performed usinis attributable to Slc7a6 more than Slc7a7 expression. Our results
point then to a central role of Slc7a6 in the regulation of arginine avail-
ability in RAW264.7.
Interestingly, preliminary experiments performed on healthy
human monocytes conﬁrmed the results obtained in mouse macro-
phages concerning the effects of PTG. The treatment causes, indeed, an
evident induction of arginase expression at both gene and protein levels
(Fig. 8), even if a great variability of response can be observed among
the different donors enrolled. On the contrary, unlike mouse macro-
phages, the simultaneous addition of IFNγ in these cells does not
strengthen the effect of PTG (results not shown).
In conclusion our results demonstrate that also arginase, besides
iNOS, is a target of PTG inmonocyte/macrophage cells. Recent literature
evidences ascribe a role to polyamines in the control of epithelial
permeability [40]. In light of this study and of our results we can thus
speculate that arginase activation and polyamine production, triggered
in innate immune cells by ingested gluten, might contribute to the
impairment of intestinal epithelial permeability in vivo. Whether
these ﬁndings may have an implication in the comprehension of
CD pathogenesis appears intriguing, although it deserves further
investigations.
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